Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 20/09/2024 pm IST			5-day change	1st Jan Change
1,715.00 ^DKK	-2.83%		-4.72%	-20.42%

16/09	Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	MT
16/09	Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Vous êtes déja client ? Log In

Latest news about Genmab A/S

Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	16/09	MT
Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	16/09	MT
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha-Targeted, Topo1 Antibody-Drug Conjugate	15/09	CI
Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	09/09	MT
Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM	04/09
Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31	04/09	MT
HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair	30/08	MT
European Equities Close Lower in Tuesday Trading; Euro Area, EU Inflation Rises Slightly	20/08	MT
Global markets live: Rio Tinto, GSK, Palo Alto, GM, Lowe's...	20/08
Genmab Wins Conditional EU Approval for Follicular Lymphoma Antibody	20/08	MT
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization	20/08	DJ
Genmab, AbbVie Get Conditional European Commission Approval for Lymphoma Treatment	20/08	MT
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	19/08	CI
Genmab Names First Chief Technology, Chief Commercial Officers; COO to Exit	16/08	MT
Genmab COO Anthony Mancini Departs; Firm Names New CTO, CCO	16/08	MT
Genmab Operations Chief Anthony Mancini Departing	16/08	MT
Genmab A/S Announces Executive Changes	16/08	CI
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly? (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process	15/08	CI
GENMAB : Better-than-expected Q2 + guidance upgrade	09/08
Genmab: updates 2024 financial forecasts	09/08	CF
Genmab's Interim Q2 Earnings, Revenue Climb; Increases 2024 Revenue Guidance	09/08	MT
Genmab Posts Higher H1 Profit; Revenue Advances	09/08	MT
Genmab A/S, H1 2024 Earnings Call, Aug 08, 2024	08/08
Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08/08	CI
Global markets live: Amazon, Intel, Boeing, Robinhood, KKR, Zillow...	08/08

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Employees

2,526

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release

More about the company